Use of extracellular vesicles and micronuclei of circulating stromal cells as pan-cancer biomarkers for predicting clinical outcomes

A method for predicting presence of metastatic spread and/or metastatic progression in a subject having cancer, said method comprising determining the presence of one or more of (a) MN, (b) EVs, (c) EPN, (d) internalized intact cells, and (e) internal cellular debris in circulating cells or produced by circulating cells of a biological sample from a subject having cancer, wherein the presence of one or more of (a), (b), (c), (d) and (e) predicts presence of metastatic spread and/or metastatic progression in the subject.

A method for predicting cancer progression in a subject having cancer comprising determining the presence of one or more of (a) MN, (b) EV, (c) EPN, (d) internalized intact cells, and (e) internal cellular debris in circulating cells or produced by circulating cells in a first biological sample and a second biological sample at a later date, and optional additional biological samples, obtained from a subject having cancer, wherein when one or more of (a), (b), (c), (d) or (e) is present in or produced by the circulating cells of the second and/or additional biological sample but not present in or produced by the circulating cells of the first biological sample, the cancer is predicted to progress in the subject, and wherein when one or more of (a), (b), (c), (d) or (e) is present in or produced by the circulating cells of the first biological sample but not present in or produced by the circulating cells of the second and/or additional biological sample, the cancer is predicted not to progress in the subject.

A method for predicting cancer progression in a subject having cancer comprising determining the presence of one or more of (a) MN, (b) EV, (c) EPN, (d) internalized intact cells, and (e) internal cellular debris in circulating cells or produced by circulating cells in a first biological sample and a second biological sample at a later date, and optional additional biological samples, obtained from a subject having cancer, wherein the first sample is obtained from the subject prior to or during cancer treatment, wherein the second sample and optional additional samples are obtained from the subject after at least one cancer treatment, wherein when one or more of (a), (b), (c), (d) or (e) is present in or produced by the circulating cells of the first biological sample but not present in or produced by the circulating cells of the second and/or additional biological sample, the cancer is predicted not to progress, and wherein when one or more of (a), (b), (c), (d) or (e) is present in the second and optional/or additional samples but not present in or produced by the circulating cells of the first biological sample, the cancer is predicted to progress.

A method for predicting response to treatment in a subject having cancer comprising determining the presence of one or more of (a) MN, (b) EV, (c) EPN, (d) internalized intact cells, and (e) internal cellular debris in circulating cells or produced by circulating cells in a first biological sample and a second biological sample at a later date, and optional additional biological samples, obtained from a subject having cancer, wherein the first sample is obtained from the subject prior to or during cancer treatment, wherein the second sample and optional additional samples are obtained from the subject after at least one cancer treatment, wherein when one or more of (a), (b), (c), (d) or (e) is present in or produced by the circulating cells of the first biological sample but not present in or produced by the circulating cells of the second and/or additional biological sample, the subject is predicted to respond to the treatment, and wherein when one or more of (a), (b), (c), (d) or (e) is present in the second and optional/or additional samples but not presence in the circulating cells of the first biological sample, the subject is predicted not to respond to the treatment.

(canceled)